Recruiting nowN/AAges 18 Years to 80 Years
Safety and Efficacy of Preoperative SBRT and Radical Surgery for Soft Tissue Sarcoma of Extremities
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University · NCT06760221 on ClinicalTrials.gov ↗
Conditions studied
Soft Tissue SarcomaStereotactic Body RadiotherapySurgery
What it tests
- stereotactic body raiotherapyradiation
Where it's running1 site
1 international site
- Recruiting now
the second affiliated hospital of Zhejiang University Hangzhou, Zhejiang, China, 310009
Hangzhou, Zhejiang, China
- Qichun Wei, MD/PhD(contact)+86 571 87783521[email protected]
- Haiyan Chen, MD/PhD(contact)+86 571 87783521[email protected]
See the official eligibility language
Shown exactly as written on ClinicalTrials.gov. Your oncologist is the right person to judge whether it fits your situation.
Inclusion Criteria: 1. Aged ≥18 years; 2. Confirmed diagnosis of soft tissue sarcomas; 3. Highly malignant soft tissue sarcomas; 4. Not received surgery, chemotherapy or other antitumor therapy; 5. ECOG (Eastern Cooperative Oncology Group) performance status 0 or 1; 6. Signed informed consent; 7. Willing to provide tissue from an excisional biopsy of a tumor lesion,willing to provide blood sample before and after treatment; Exclusion Criteria: 1. Patients with soft tissue sarcoma of extremities with shallow tumor location, small size, low grade pathology and operable surgical resection; 2. Distant metastasis; 3. Received surgery or chemotherapy or other antitumor therapy; 4. Previously participated in other clinical trials; 5. History of severe allergies, patients with allergic conditions, such as contrast agent allergy; 6. Known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy, or in situ cervical cancer. 7. Diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy; 8. Active infection requiring systemic therapy; 9. Known psychiatric or substance abuse disorders ; 10. Pregnant or breastfeeding; 11. Known history of human immunodeficiency virus (HIV: HIV 1/2 antibodies); 12. Received a live vaccine within 30 days before radiotherapy. 13. Unable to lie flat.
Updated 2025-01-06 on ClinicalTrials.gov. Always confirm current details with the study team or your oncologist.